Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines
Biotheranostics announces recommendations for Breast Cancer Index in both the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and the American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer. Breast Cancer Index was endorsed as a multi-gene assay to aid in decisions regarding both the addition of chemotherapy and extended adjuvant endocrine therapy for patients with early-stage breast cancer.
Two key treatment decisions are priorities in the management of estrogen receptor positive (ER+) early-stage breast cancer: the first, whether the patient is of sufficient risk of recurrence to recommend systemic chemotherapy in addition to adjuvant endocrine therapy, and the second, whether to recommend extended endocrine therapy beyond the initial primary 5 years of adjuvant endocrine therapy. For each treatment decision, physicians and patients must determine whether the potential benefit from the additional therapy is likely to outweigh the potential risks of serious toxicities and side effects of treatment.
For more click here